Microbiome Therapies in Inflammatory Bowel Disease, Diabetes and Obesity: From Mechanistic Insights to Clinical Translation.

INTRODUCTION: This study aims to explore novel clinical microbiome therapeutics for Inflammatory Bowel Disease (IBD), diabetes, and obesity. Specifically, this work seeks to elucidate the efficacy, underlying mechanisms, and therapeutic potential of microbiome-based interventions for various chronic diseases by identifying recent findings from microbiome research, clinical trials, and meta-analyses. METHODS: Literature data for the present study were collected through a structured narrative review using databases such as PubMed, Google Scholar, and clinical trial registries. We searched for evidence published between 2013 and 2024, with a particular focus on randomized controlled trials and meta-analyses of microbiome approaches for IBD, diabetes, and obesity. RESULTS: Gut microbiome therapies with promising effects in IBD, diabetes, and obesity include probiotics, prebiotics, Fecal Microbiota Transplantation (FMT), engineered bacterial therapies, and dietary interventions. These interventions have been shown to reduce inflammation, enhance insulin sensitivity, promote weight loss, and promote metabolic health. These effects are mediated by modulation of the immune response, metabolic control via microbial metabolites, and restoration of microbial balance and homeostasis. DISCUSSION: Microbiome-based therapies show promise in modulating inflammation and metabolism in chronic diseases; however, variable efficacy, limited large-scale clinical evidence, and mechanistic heterogeneity necessitate cautious interpretation and further validation. CONCLUSION: Microbiome therapies, being effective and safe, pose a risk of completely overturning current treatment paradigms. Future applications need to focus on combination therapies, personalized medicine, and technological advances to realize the potential of microbiome-based interventions to promote good patient health and quality of life.